HALOZYME THERAPEUTICS, INC. Quarterly Deferred Income Tax Liabilities, Net in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
Halozyme Therapeutics, Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q4 2021 to Q3 2024.
  • Halozyme Therapeutics, Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2024 was $12M.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $12M Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $13.6M Jun 30, 2024 10-Q 2024-08-06
Q4 2023 $0 Dec 31, 2023 10-Q 2024-10-31
Q3 2022 $29M Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $3.29M Jun 30, 2022 10-Q 2022-08-09
Q4 2021 $0 Dec 31, 2021 10-Q 2022-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.